Allopurinol versus usual care in UK patients with ischaemic heart disease (ALL-HEART): a multicentre, prospective, randomised, open-label, blinded-endpoint trial

Isla S. Mackenzie*, Christopher J. Hawkey, Ian Ford, Nicola Greenlaw, Filippo Pigazzani, Amy Rogers, Allan D. Struthers, Alan G. Begg, Li Wei, Anthony J. Avery, Jaspal S. Taggar, Andrew Walker, Suzanne L. Duce, Rebecca J. Barr, Jennifer S. Dumbleton, Evelien D. Rooke, Jonathan N. Townend, Lewis D. Ritchie, Thomas M. MacDonald, Husnat AhmedPeter Arthur, Jane Aziz, Lawrence Barnes, Sarah Boyle, Tom Brighton, Morris Brown, Mark Caulfield, Jesse Dawson, Martin Denvir, Alexander SF Doney, Sagar Doshi, Moira Dryburgh, Michael Eddleston, Jim Finlayson, Ahmet Fuat, Jacqueline Furnace, JW Kerr Grieve, Greg Guthrie, Sharon Ham, Emma Isaard, Claudine Jennings, Richard Johnson, Claire Kerr, Sohail Khan, Kailash Krishnan, Susan Long, Anne Mackintosh, Mary Joan Macleod, Terry McCormack, Christopher Weir, ALL-HEART Study Group

*Corresponding author for this work

Research output: Contribution to journal › Article › peer-review

64 Citations (Scopus)
1 Downloads (Pure)

Fingerprint

Dive into the research topics of 'Allopurinol versus usual care in UK patients with ischaemic heart disease (ALL-HEART): a multicentre, prospective, randomised, open-label, blinded-endpoint trial'. Together they form a unique fingerprint.

Medicine & Life Sciences